> HaYa Therapeutics and GNUbiotics became the first companies to join the Swiss Biopole startup incubator. The startups will move into the facility when it opens in the spring of 2018, becoming the first of the 10 to 12 companies Biopole expects to host at any one time. Statement (PDF)
> Carrick Therapeutics dosed the first patient in a phase 1 trial of its cyclin-dependent Kinase 7 selective inhibitor. The cancer candidate is expected to move into an efficacy trial next year. Release
> Gene therapy startup Orchard Therapeutics expanded its technical operations in California. The expansion quadruples the U.K. biotech’s technical operations laboratory footprint. Statement
> Symphogen pocketed a $5 million (€4 million) milestone after Roche’s Genentech moved a Staphylococcus aureus candidate into phase 1b. Release
> Analysts talked up the prospect of Johnson & Johnson buying Genmab. Reuters